DEV Community: Jitendra Devabhaktuni

Stop Faking Your Test Data: Why `Faker.js` Breaks the Moment You Have Foreign Keys

Jitendra Devabhaktuni — Mon, 03 Aug 2026 06:54:52 +0000

A developer's guide to why independent row generation fails for relational systems, and how to fix it in under a minute

The Problem Every Backend Dev Has Hit

You need test data. So you reach for Faker, or Mockaroo, or write a quick script with numpy.random.

It works great, until your schema has more than one table.

// This "works" but it's already broken
const users = Array.from({ length: 1000 }, () => ({
  id: faker.string.uuid(),
  name: faker.person.fullName(),
  email: faker.internet.email(),
}));

const orders = Array.from({ length: 5000 }, () => ({
  id: faker.string.uuid(),
  userId: faker.string.uuid(), // <-- this ID doesn't exist in `users`
  amount: faker.commerce.price(),
}));

That userId field looks fine. It's a valid UUID format. It passes type checks. And it references a user that doesn't exist anywhere in your users table.

Run your app against this and you'll get orphaned foreign keys, broken joins, and integration tests that pass locally but reveal nothing about how your actual queries will behave once the join clause runs.

This is the single most common failure mode in test data generation, and almost nobody talks about it because faker-style tools were never built to solve it.

Why Independent Row Generation Doesn't Scale to Real Schemas

Faker and Mockaroo generate independent rows. Each table is populated in isolation, with no concept of the other tables around it. That's fine for a single flat CSV. It falls apart the moment your schema has: https://db.synthehol.ai/

Foreign keys — orders referencing users, line items referencing orders, refunds referencing payments
Composite unique constraints — one review per user per product, one booking per room per date range
Correlated columns across tables — lifetime value that should scale with order count, account tenure that should predict loan approval likelihood
Temporal ordering — a refund can't happen before the order it refunds, a subscription can't renew before it starts

None of this is exotic. It's just... what a real production schema looks like. And most synthetic data tools quietly assume you don't have it.

What "Relational" Actually Means for Test Data

Here's the distinction that matters: generating rows vs. generating a database.

	Row-Level Generators (Faker, Mockaroo)	Relational Generators
Output	Independent tables	Linked, joinable tables
Foreign keys	Random values, often invalid	Resolve to real parent rows
Cross-table correlation	None	Preserved (e.g., LTV scales with order count)
Constraint validation	Manual, after the fact	Built into generation
Temporal consistency	Not handled	Enforced (no refund before order)

If you've ever written a post-processing script to "fix up" your fake data so the foreign keys actually resolve, you've already discovered why this distinction matters. You were doing, by hand, what a relational generator should do automatically.

A Quick Way to See the Difference

Try this experiment on your own schema. Take any two related tables — say orders and order_items — and check referential integrity after generating fake data with your current tool:

import pandas as pd

orders = pd.read_csv('fake_orders.csv')
order_items = pd.read_csv('fake_order_items.csv')

orphaned = order_items[~order_items['order_id'].isin(orders['order_id'])]
print(f"Orphaned order_items: {len(orphaned)} out of {len(order_items)}")

If you're using independent row generation, that orphaned count is almost never zero. Every orphaned row is a foreign key that will throw an error, fail silently, or worse, get "handled" by application code masking a data integrity bug that won't show up until production.

How Relational Generation Actually Works

A schema-aware generator has to do three things that Faker-style tools skip entirely:

1. Understand generation order. Parent tables generate before child tables. Users exist before orders exist before order items exist. This sounds obvious until you're hand-writing a generation script and realize you have circular dependencies to untangle.

2. Sample foreign keys from existing parent rows, not from a random UUID generator:

# Instead of this:
order['user_id'] = fake.uuid4()

# You need this:
order['user_id'] = random.choice(existing_user_ids)

3. Preserve statistically realistic correlations across the relationship. A user with 2 years of tenure and 40 orders should have a meaningfully different lifetime value than a user with 2 weeks of tenure and 1 order. If your generator can't express that, your test data will train models, validate UI edge cases, and stress-test pipelines against a world that doesn't resemble production.

Where This Gets Genuinely Hard

If you've tried to build this yourself, you know where it gets painful fast:

Many-to-many relationships (users ↔ roles ↔ permissions) need junction tables generated with realistic overlap, not random pairings
Composite unique constraints (UNIQUE(user_id, product_id) on a reviews table) need generation-time collision checking, not post-hoc deduplication
Self-referencing tables (an employees table with a manager_id pointing to another row in the same table) need cycle-safe generation
Schema migrations mean your fake data generator needs to stay in sync with your actual DDL, or it silently drifts out of date

At a certain schema complexity, hand-rolling this stops being a reasonable use of engineering time. This is exactly the gap SyntheholDB was built to close.

What SyntheholDB Does Differently

Instead of generating rows, SyntheholDB generates databases. You describe your schema, or import your actual CSVs or DDL, and it handles the relational logic for you: https://db.synthehol.ai/

Define Your Schema → Generate → Export

Foreign keys resolve automatically — every child row references a real, existing parent row, not a random UUID https://db.synthehol.ai/
Composite unique constraints, non-overlapping windows, and monotonic timelines are validated and repaired before export https://db.synthehol.ai/
Cross-column correlations are tunable — lifetime value scales with order count, salary scales with tenure, the derived metrics stay believable instead of arbitrary https://db.synthehol.ai/
Zero real PII, by construction — values are sampled from statistical models, never copied or masked from production data, so there's nothing sensitive to review before you ship the dataset to a dev environment https://db.synthehol.ai/
Multiple export formats — CSV works on every plan, with SQL dumps and Parquet available for larger workflows https://db.synthehol.ai/

You can start from a template, upload existing CSVs for automatic schema inference, or just describe your data model in plain English and let the generation engine build the tables, relationships, and constraints for you. https://db.synthehol.ai/

Try It on Your Own Schema

The fastest way to see the difference is to run your actual schema through it. The free tier is capped at 1,000 rows per generation, which is enough to validate referential integrity on a real multi-table schema before you commit to anything. https://db.synthehol.ai/

👉 Generate your first relational dataset free at https://db.synthehol.ai/

If you're testing this against a schema with foreign keys, composite constraints, or many-to-many joins, drop a comment below; I'd genuinely like to hear what breaks and what doesn't. That feedback loop is exactly how tools like this get better for the rest of us.

PCI DSS 4.0 Just Made Your Staging Database a Liability. Here Is the Fix

Jitendra Devabhaktuni — Tue, 21 Jul 2026 07:40:39 +0000

PCI DSS 3.2.1 was formally retired in 2024. The only version in effect now is PCI DSS 4.0.1, and it changes what "compliant enough" means for engineering teams, not just for compliance officers.

If your team builds anything that stores, processes, or transmits a Primary Account Number (PAN), even for a second, you are in scope. And under 4.0.1, being in scope means continuous, evidenced controls, not a once-a-year audit sprint. That shift lands directly on engineering, and it lands hardest in the place most fintech teams have quietly ignored for years: staging and test environments.

The Staging Environment Nobody Wants to Audit

Ask most fintech engineering teams where their test data comes from, and the honest answer is usually some version of: a masked copy of production, refreshed whenever someone remembers, running in an environment that was never designed with PCI scope in mind.

That answer does not survive a 4.0.1 assessment.

The standard's biggest lever for reducing audit cost and risk is scope reduction: can you avoid touching card data entirely in a given system. Every environment that stores, processes, or transmits a PAN falls in scope, and scope is where compliance cost and breach risk both concentrate. A staging database seeded from a production extract, even a masked one, keeps that environment inside your Cardholder Data Environment (CDE) unless the masking was rigorous enough to fully remove PAN, which in practice it frequently is not.

The most common audit failure is not the payment flow itself. It is a PAN that slipped into an application log, a support tool, or a staging database that nobody thought to scope.

What 4.0.1 Specifically Changes for Engineering Teams?

Most of the roughly 60 new requirements in 4.0 turn point-in-time checks into continuous, evidenced practice. The ones that hit engineering teams directly:

MFA is now required for every path into the cardholder data environment, not just admin access or remote access. Every user, every service account, every path.

Third-party and custom scripts on any payment page must be inventoried and integrity-checked, a direct response to Magecart-style skimming attacks.

Targeted risk analysis now requires documented reasoning for testing frequency. "We do it annually because we always have" does not survive an assessor's questions anymore.

Every control needs a named owner. Auditors ask who owns a requirement and expect a specific answer, not a team name.

The through-line across all of these changes: 4.0.1 rewards teams that already log, monitor, and document as part of engineering, and it penalizes teams that treat compliance as a separate workstream bolted on before an audit.

Staging and test data infrastructure sits squarely inside this shift. If your CI pipeline seeds a database from a production extract, that pipeline is now part of your continuous, evidenced control surface, whether you designed it to be or not.

Why Masking a Production Copy Does Not Actually Solve This?

Column-level masking feels like it solves the problem. It does not solve it completely, and the parts it fails to solve are exactly the parts an assessor is trained to look for.

Masking a name or a card number in a copied production table does not remove the underlying transaction patterns, the customer relationship structure, or the temporal sequencing that came from real financial activity. If a masking script misses a single field, a single log line, or a single downstream export, that PAN or that reconstructable transaction pattern is now sitting in an environment that was never scoped, monitored, or access-controlled the way your CDE is.

And masking has to be re-verified every time the schema changes, every time a new field is added, every time a new export path is built. That verification burden compounds every sprint. Most teams do not re-verify it every sprint. They verify it once, at setup, and assume it still holds a year later.

A synthetic database generated from statistical models rather than transformed from a production source does not have this problem, because there is no real PAN or real transaction history in the pipeline at any point to miss.

What Core Banking and Payments Test Data Actually Requires?

Payments and core banking data is relationally dense in a way that makes weak test data especially dangerous. A single transaction record touches accounts, counterparties, KYC status, risk flags, authorization codes, and settlement records. Realistic testing requires all of that to be correct and linked, not just individually plausible.

Core banking testing specifically requires valid KYC combinations, regulatory boundary cases, interest rate permutations, and NPA (non-performing asset) classifications, alongside the negative test cases and edge scenarios that reveal how a system fails, not just how it succeeds. Randomly generated test data almost never produces this combination correctly. Independent field generation misses the correlations between account risk tier, transaction velocity, and authorization outcomes that a real fraud detection or underwriting model depends on to behave correctly.

A synthetic database built for this domain needs five properties that most ad hoc test data setups do not have together: schema-aware generation that respects your actual table structure and foreign keys, domain-aware correlations between account risk, transaction patterns, and authorization outcomes, temporal consistency so that authorization precedes settlement and KYC precedes account activation, edge case coverage that includes the boundary conditions regulators and fraud models are built to catch, and full reproducibility so a bug found in staging can be reproduced from a documented seed.

How SyntheholDB Fits Into a PCI-Scoped Engineering Stack?

SyntheholDB generates production-realistic synthetic databases without ever touching a real PAN, a real account record, or any production data source. That single property changes the compliance conversation for every environment it touches.

A staging database generated by SyntheholDB is never inside your PCI scope in the way a masked production copy is, because there was never a real cardholder data element in the generation pipeline to leak, mismask, or forget to scrub. This is the scope-reduction strategy PCI DSS 4.0.1 itself recommends, applied to your test infrastructure instead of your payment flow.

For core banking and payments engineering specifically, SyntheholDB generates schema-aware databases with domain-aware correlations across accounts, transactions, KYC status, and risk flags, referential integrity enforced across every linked table, and edge cases and boundary conditions built into the generation by design rather than left to chance. On CI, deterministic seed-based generation through the SyntheholDB API means every pipeline run gets a fresh, consistent, realistic database, with no stale fixtures and no PAN ever touching a log, a test database, or a support tool.

Every generation ships with a fidelity score, a privacy label scan, and a referential integrity report. When an assessor asks how your non-production environments are scoped and governed, the answer is complete and documented before the question is finished, which is precisely the continuous, evidenced posture 4.0.1 expects.

A Practical Path to Removing PAN from Your Test Stack
Start with the service in your stack with the highest cardholder data exposure risk in staging: the one whose test database was most recently refreshed from a production extract, or the one closest to your payment authorization flow.

Export or describe its schema in SyntheholDB. Generate a synthetic database at the population size your test suite needs. Wire your service and CI pipeline to the synthetic database instead of the masked production copy. Run your full regression and integration suite and measure what the realistic data surfaces that your previous fixtures did not.

Once that service runs cleanly against synthetic data, decommission the masked production copy it used to depend on, and document the decommission as evidence of scope reduction for your next assessment.

Try It Free

SyntheholDB is free to start. No credit card required. Your first synthetic database is ready in under 60 seconds.

If your team has already gone through a PCI DSS 4.0.1 assessment this year, drop a comment with what surprised you most about the new scope expectations. The answers from this community shape what gets built into the platform next.

How Clinical Research Engineers Can Kill the PHI Sprawl Problem in Staging Environments

Jitendra Devabhaktuni — Mon, 13 Jul 2026 10:55:22 +0000

There is a problem in clinical research engineering that almost everyone has and almost no one talks about out loud.

Your staging environment has PHI in it.

Not because someone made a reckless decision. Because the realistic alternative, building and maintaining a synthetic clinical database that actually behaves like production across all your linked tables, has historically been harder than just copying the production database and calling it de-identified.

The result is PHI sprawl: protected health information quietly living in development, staging, QA, CI, vendor sandboxes, and sometimes laptop-local databases because the path to realistic synthetic data was too expensive, too slow, or too fragile to maintain.

This article is a practical guide to eliminating that sprawl without sacrificing the data realism your pipelines depend on.

Why PHI Sprawl Happens in Clinical Engineering Teams
Clinical data is inherently relational and inherently complex. A single patient encounter touches at least six tables in a standard EHR schema: patients, encounters, diagnoses, prescriptions, procedures, and lab results. A realistic pipeline test requires all of those tables to be populated with consistent, linked, temporally ordered data.

The standard approaches most teams fall back on all have critical failure modes.

Faker and Random Generation
Faker fills columns with plausible values in isolation. It does not understand that a patient with a Type 2 diabetes diagnosis should have metformin in their prescription table, an HbA1c in their lab results, and an endocrinology encounter in their encounter history. It fills those tables independently. Your pipeline gets data that passes a null check but fails the moment you run a real query across two tables.

De-identified Production Copies
De-identification sounds rigorous until you look at what it actually produces in most engineering workflows. A column-level de-identification pass replaces names and dates with tokens. The underlying patient relationships, the clinical patterns, the temporal ordering, all of it is still there. Re-identification risk is real. And more practically, that de-identified copy still counts as PHI under HIPAA because de-identification under the Safe Harbor method requires removing 18 specific identifier types, a process most engineering teams are not performing rigorously on every refresh cycle.

The average cost of a healthcare data breach reached $7.42 million in 2025, with 279 days to identify and contain. Every additional environment where PHI lives, including staging environments your team did not intend to classify as PHI-bearing, expands your breach surface and your audit scope.

Handcrafted Seed Files
Manually maintained fixture files solve neither the realism problem nor the compliance problem. They require constant maintenance as schemas evolve, they cover only the happy-path scenarios that someone thought to script, and they frequently contain real patient data that was copied once during initial setup and never reviewed again.

The PHI Sprawl Audit Most Teams Have Never Done
Before looking at solutions, it helps to know the actual scope of the problem on your team.

Run through these questions honestly:

How many non-production environments in your infrastructure contain a copy of clinical data that originated from production, even partially?

When was the last time each of those environments was refreshed, and was a de-identification or masking step applied on that refresh?

Do your vendor partners, QA contractors, or external CRO technical teams have access to any of those environments?

Does your CI pipeline seed its test database from a fixture that was originally derived from production data?

Could you produce a complete data flow diagram showing every system where patient data lives outside of production, and could that diagram survive a HIPAA audit?

Most engineering teams that run this exercise discover they have more PHI sprawl than they thought. The discovery is not a failure of intent. It is a failure of tooling. The tools for generating realistic synthetic clinical databases on demand did not exist at the quality and speed needed, so teams used what worked.

SyntheholDB exists to close that gap.

What a PHI-Free Clinical Engineering Stack Actually Requires
Eliminating PHI sprawl from your engineering environments is not a policy change. It is an infrastructure change. You need a way to generate synthetic clinical databases that are realistic enough that your pipelines, your integration tests, and your staging demos all behave like production.

That requires five specific properties that most synthetic data tools do not deliver together.

Schema-Aware Generation
Your synthetic database must match your actual schema, not a generic clinical schema or a research-oriented data model. Foreign keys must be resolved correctly. Composite unique constraints must be respected. Non-nullable fields must always be populated. SyntheholDB accepts your schema as a SQL DDL file, a JSON schema definition, a CSV import, or a plain-English description and enforces every constraint during generation, not after.

Cross-Table Relational Consistency
Every patient in your patients table must have corresponding records in every linked table at the correct cardinalities. An encounter must exist before a diagnosis linked to that encounter. A prescription must reference a valid encounter and a valid diagnosis code. Lab results must link to valid patients and valid encounter IDs. SyntheholDB enforces this consistency during generation across all tables simultaneously.

Temporal Ordering Across the Full Schema
Clinical data is time-dependent. Diagnosis dates must precede related treatment dates. Treatment dates must precede outcome dates. Admission timestamps must precede discharge timestamps. A deceased patient must not have encounters after their recorded date of death. SyntheholDB enforces temporal ordering across all linked tables in a single generation pass, not table by table.

Domain-Aware Field Correlations
Realistic clinical data is not randomly distributed. Age correlates with comorbidity burden. Diagnosis codes correlate with linked prescription codes. Lab values correlate with diagnosis severity. Encounter frequency correlates with chronic condition management patterns. SyntheholDB uses domain-specific statistical models to reproduce these correlations at any population scale.

Reproducibility From a Documented Seed
When a bug appears in staging that you cannot reproduce locally, the problem is almost always that the two environments were generated differently. SyntheholDB generates reproducible databases from a documented schema and seed. The same inputs produce the same database on every run, in every environment.

How to Migrate One Service Off PHI Today
You do not need to migrate your entire stack to eliminate PHI sprawl. Start with one service.

The best candidate is the service with the highest PHI exposure risk: the one whose staging environment was last refreshed from production most recently, or the one that handles the most sensitive clinical tables.

Step 1: Export or define the schema

Export your service schema as a SQL DDL file or describe your core entities in plain English inside SyntheholDB. The generation pipeline builds a complete schema definition from your input and surfaces only genuine ambiguities before generation begins.

Step 2: Generate a synthetic database

Configure the population size you need: a few thousand records for unit tests, tens of thousands for integration tests, hundreds of thousands for performance and staging environments. Generate. Review the fidelity score, the privacy label report, and the referential integrity report that ship with every generation before the export reaches your environment.

Step 3: Wire your service to the synthetic database

Replace your staging database connection string with a connection to the generated synthetic database. Run your full test suite. Run your integration tests. Run your staging demo workflows. Measure how many test failures the realistic data surfaces that your previous fixtures did not.

Step 4: Add generation to your CI pipeline

On Pro and above, the SyntheholDB API supports deterministic generation with a documented seed. Add a generation step to your CI pipeline that rebuilds the synthetic database from a pinned schema and seed on every run. Every pipeline run gets a fresh, consistent, realistic database with no stale fixtures and no fixture drift.

Step 5: Decommission the PHI-bearing environment

Once your service runs correctly against the synthetic database in staging and CI, the PHI-bearing copy of that environment can be decommissioned. Document the decommission for your audit trail. That documentation is now complete and defensible.

OMOP CDM Teams: What This Changes for Your Workflow
If your team works with OMOP CDM schemas, SyntheholDB generates synthetic databases that conform to your OMOP CDM design directly. You define the CDM version, specify your target tables, and the generation engine produces a populated, relationally consistent OMOP dataset without any production data involvement.

This changes three specific parts of the OMOP engineering workflow.

ETL pipeline development no longer requires a copy of source data. You generate a synthetic source dataset in your source schema, run your ETL, and validate the output against a synthetic OMOP target. The full pipeline is developed and tested without production data at any stage.

ATLAS and OHDSI tool integration testing gets a realistic dataset to run against. Cohort definitions, patient-level prediction studies, and incidence rate calculations all behave correctly against a synthetic OMOP database generated at the right population size and distribution.

Federated network study preparation becomes simpler. When you need to test a study package against a local CDM before a network run, you generate a synthetic CDM that matches your institution schema and test against that. No production data leaves your systems during development.

The Compliance Posture This Creates
Every SyntheholDB generation produces three artifacts alongside the database export.

A fidelity score documenting the statistical similarity between the generated database and the input schema distributions.

A privacy label report scanning every field in every table for sensitive-shaped values and flagging them before export.

A referential integrity report confirming that every foreign key, every composite unique key, and every temporal constraint holds across the full generated database.

These three artifacts answer a HIPAA audit, a SOC 2 review, or an enterprise customer security questionnaire when they ask how your non-production environments are governed. SyntheholDB is SOC 2 Type II certified, ISO 27001 certified, HIPAA compliant, and GDPR compliant. Enterprise deployments run fully on-premises with no external network calls in the generation or validation path.

What This Looks Like Six Months From Now
A team that migrates its clinical staging and CI environments to SyntheholDB-generated synthetic databases over the next six months ends up in a measurably different position.

PHI no longer lives outside production. Every environment that used to require a de-identification step or a compliance exception now runs on data that was never real. The audit answer is simple and complete: non-production environments contain no patient data because they were never seeded with patient data.

Test coverage improves. Synthetic databases generated with domain-aware correlations and edge case coverage surface bugs that fixture-based environments never reached.

Environment provisioning time drops to under 60 seconds. A developer who needs a realistic clinical database for a new feature branch gets one immediately, not after a three-day provisioning request.

Vendor and contractor onboarding becomes frictionless. Handing a CRO partner or a QA contractor a synthetic database requires no legal review, no data transfer agreement, and no compliance exception.

Try It Free
SyntheholDB is free to start. No credit card required. Your first synthetic clinical database is ready in under 60 seconds.

If you try it on a clinical schema, especially an OMOP CDM schema or a FHIR-mapped schema, drop a comment below and share what you found. What did the realistic data surface that your previous fixtures did not? What did you remove from your fixture maintenance backlog?

The answers from this community shape what gets built into the platform next.

Your Clinical Database Is Lying to You (And You Already Know It)

Jitendra Devabhaktuni — Mon, 06 Jul 2026 08:49:17 +0000

There is a specific moment most clinical data engineers recognize immediately.

You are three weeks from a database lock. The analysis pipeline has been running clean in staging for two months. QA has signed off. The biostatistics team is ready.

Then you move to production data, and something breaks. A temporal sequence that your synthetic environment never generated. A patient with 14 overlapping prescriptions that your schema constraints never enforced. An encounter record with no linked diagnosis that your test fixtures never included because nobody thought to create that edge case.

The post-mortem always arrives at the same conclusion: the synthetic environment did not behave like production.

This article is about why that happens, what it costs, and how to build clinical test databases that actually hold up when it matters.

The Root Cause Nobody Wants to Admit

Most clinical engineering teams generate test data the same way teams generated it ten years ago.

A Python script. A few Faker calls. Some hardcoded patient IDs. Maybe a CSV import of de-identified records from a study that ended in 2019.

The data looks fine when you query a single table. It falls apart the moment your application does anything real: a join across patients and encounters, a temporal query across diagnoses and prescriptions, a cohort filter that requires linked lab results.

The reason is structural. Most test data generation treats tables as independent. It fills columns with plausible values without modeling the relationships between those values across the full schema. Blood pressure readings are not correlated with age or diagnosis burden. Prescription records reference patient IDs that exist in the patients table but not in the encounter table that should have preceded them. Outcome dates precede treatment dates. Deceased patients have follow-up encounters.

Your application is being tested against a world that does not behave like the world it will run in.

What a Clinical Database Actually Contains

Before solving the problem, it helps to be precise about what makes clinical data structurally complex.

A production clinical database is not a collection of tables with plausible values. It is a network of constrained, time-ordered, domain-governed relationships.

Patients have demographics that correlate with comorbidity burden. A 72-year-old patient with a recorded diagnosis of Type 2 diabetes should have a medication history that reflects standard treatment pathways, lab values that stay within ranges consistent with their condition, and encounter frequency that reflects typical management patterns for that population.

Encounters are time-ordered. They have admission types that constrain valid procedure codes. They have discharge dispositions that constrain subsequent encounter types. A patient discharged to hospice does not return for a routine outpatient visit.

Diagnoses carry severity classifications that constrain treatment patterns. A fatal adverse event is not labeled mild. A resolved acute condition does not appear as active in a subsequent encounter without a new diagnosis event.

Prescriptions have therapeutic relationships to diagnoses. Dosing correlates with patient weight, age, and renal function. Duration correlates with condition type. Renewals follow clinically plausible timelines.

Lab results have reference ranges that are population-dependent. Values outside those ranges should correspond to documented clinical events. Abnormal results without a linked follow-up encounter are a red flag in production data and should be a red flag in synthetic data too.

None of these relationships are modeled by a Faker script. All of them are enforced in production. The gap between those two realities is where your test environment lies to you.

The Three Failure Patterns Clinical Engineers Hit Most

Pattern 1: The Silent Referential Break

Your application runs a join between encounters and diagnoses. In your synthetic database, 3% of encounter records have no linked diagnosis because your test data generator created them independently. In production, that percentage is 0% because the system enforces the constraint at ingestion.

Your join returns slightly wrong results in staging. You do not notice because you are not testing for it. You notice in production when a cohort query returns a number that does not match the site coordinator report.

Pattern 2: The Temporal Inversion

Your pipeline calculates time-to-event metrics. In your synthetic database, a small percentage of records have treatment dates that precede diagnosis dates because your generator populated each table independently without enforcing cross-table temporal ordering.

Your pipeline runs clean in staging. In production, the time-to-event calculation throws an exception on the first record it hits where the constraint holds. You spend two days debugging a pipeline that was never actually tested against realistic data.

Pattern 3: The Missing Edge Case

Your application handles patient transfers between care settings. In your synthetic database, every patient follows a standard inpatient to outpatient pathway because your test fixtures were built from a happy-path scenario.

In production, 8% of patients have a transfer record with a gap in coverage, which your application was never tested against. Your staging environment never surfaced this because nobody generated that edge case, and Faker does not know it should exist.

What a Production-Realistic Clinical Database Requires

A synthetic clinical database that actually behaves like production needs five things that most test data tools do not provide.

Schema-first generation. The database structure must drive the generation process, not the other way around. Referential integrity is not something you add after generating rows. It is the constraint that determines which rows are valid to generate in the first place.

Domain-governed field correlations. Values in a clinical database are not independently distributed. Every field that correlates with another field in production should correlate in the same direction in your synthetic environment. This requires a generation engine that understands clinical domain rules, not just statistical distributions.

Cross-table temporal ordering. Events in a clinical database happen in sequences that respect real-world causality. A generation engine that populates tables independently cannot enforce these sequences. The ordering must be enforced at the generation layer, across all tables simultaneously.

Edge case coverage by design. A production-realistic clinical database should include the edge cases that appear in real patient populations: patients with no recorded diagnoses, encounters with atypical discharge dispositions, prescriptions with duration anomalies, lab results flagged as critical. These are not errors. They are the scenarios your application needs to handle.

Reproducibility. When a bug appears in staging that you cannot reproduce in your local environment, the problem is usually that the two environments were generated differently. A clinical test database should be reproducible from a documented configuration. Same inputs, same database, every time.

How SyntheholDB Addresses This for Clinical Teams

SyntheholDB was built specifically to close the gap between what clinical test environments look like and what production systems actually contain.

The generation pipeline works from your schema outward. You import a schema, describe your data model in plain language, or start from the built-in Healthcare EHR template, which covers patients, providers, encounters, diagnoses, prescriptions, procedures, lab results, and outcomes at production scale: 500,000 encounters, 750,000 diagnoses, fully linked across every table.

The engine enforces referential integrity at generation time, not as a post-processing validation step. Foreign keys are resolved before rows are written. Composite unique keys are tracked across the full generation run. Temporal sequences are ordered across linked tables simultaneously, not table by table.

Domain-aware correlation models handle the field-level relationships that distinguish realistic clinical data from plausible-looking random values. A patient profile includes correlated demographics, comorbidity burden, and medication history that reflect realistic population distributions. Lab values stay within ranges appropriate to the patient profile. Encounter frequency reflects condition management patterns.

Edge cases are generated by design. The engine includes anomalous but clinically valid patterns: patients with gaps in care, encounters with atypical disposition codes, prescriptions at the boundaries of therapeutic ranges, lab results flagged for clinical review. These are not injected manually. They emerge from the domain models built into the generation pipeline.

Every export includes a fidelity score, a privacy label scan, and a referential integrity report. When your compliance team or a regulatory auditor asks how your test environment was validated, the documentation is already there.

SyntheholDB is SOC 2 Type II certified, ISO 27001 certified, HIPAA compliant, and GDPR compliant. Enterprise deployments run fully on-premises with no external network calls in the generation or validation path.

A Practical Migration Path

If your team is currently running on Faker scripts, de-identified dumps, or manually maintained seed data, moving to a production-realistic synthetic database does not require a big-bang migration.

Start with one service. Pick the service in your stack that has the most complex data dependencies, the most frequent staging failures, or the longest environment provisioning time. Export or define its schema. Generate a synthetic database scoped to that service using SyntheholDB. Wire your service and its tests to that synthetic database.

Measure three things: how long it took to provision a realistic environment compared to your current approach, how many of your current test fixtures you were able to delete, and whether your staging failure rate on that service changed.

If the answer confirms what most clinical engineering teams find, which is that the realistic environment catches more real issues and requires less manual maintenance, you have a concrete case to expand the approach across your stack.

The Bottom Line for Clinical Engineers

A synthetic database that does not behave like production is not a test environment. It is a confidence trap. It lets you ship features that have never been tested against the real conditions they will run in, and it surfaces the failures at the worst possible time.

The standard for clinical data environments should be the same standard you hold for your production systems: correct schemas, enforced constraints, realistic relationships, and reproducible configurations.

SyntheholDB is free to start. No credit card required. Your first synthetic clinical database is ready in under 60 seconds.

If you try it on a clinical schema, drop a comment below and share what you found. What edge cases did the synthetic database surface that your current test environment was missing? The answers from this community consistently shape what gets built into the platform next.

Why Synthetic Data Is the Biggest Game Changer Pharma and Biotech Research Teams Are Not Fully Using Yet

Jitendra Devabhaktuni — Tue, 30 Jun 2026 11:11:46 +0000

Every pharma and biotech research team is racing against the same clock. Drug development takes an average of ten to fifteen years and costs over one billion dollars per approved therapy. Clinical trials account for the most time-consuming and expensive leg of that journey, and 85% of all trials face delays. When researchers at a large hospital research institute were asked about their biggest barrier to progress, 51% named the same thing: waiting for data access. Not funding. Not talent. Not technology. Data access.

The irony is devastating. The data already exists. It sits in electronic health record systems, genomic repositories, sponsor databases, CRO servers, and institutional archives. But getting to it requires months of legal review, IRB approvals, data use agreements, and cross-border compliance checks. By the time a team gains access to a dataset they need for an analysis, the research window may have shifted entirely.

This is the problem that synthetic data solves. And in 2026, it is no longer an experimental concept. It is becoming a foundational infrastructure layer for pharma and biotech organizations that want to move faster without compromising compliance or scientific integrity.

The Real Cost of the Data Access Problem

Numbers are sobering when you look at them squarely. The Tufts Center for the Study of Drug Development found that a single day of delay in drug development costs approximately 500,000 dollars in unrealized prescription drug sales. The direct daily cost to run a Phase III trial sits at over 55,000 dollars per day. Compounded across a pipeline with multiple programs in simultaneous development, these delays represent billions in lost value annually across the industry.

Data fragmentation is a major driver of those delays. Pharma R&D data lives in silos across sponsors, contract research organizations, health systems, and geographic markets. Transferring that data across organizational and national boundaries requires complex legal and administrative procedures. In rare disease research, where a single institution may hold records for only a handful of patients globally, the data access burden becomes a direct barrier to generating any meaningful evidence at all.

The traditional response has been to route everything through a central access gateway, anonymize or mask production data, and distribute sanitized datasets on a case-by-case basis. This process is slow, it does not scale, and it still carries residual re-identification risk every time sensitive data moves from one environment to another. Synthetic data offers a fundamentally different architecture.

What Synthetic Data Actually Means for Research Teams

Synthetic data in the pharma and biotech context refers to artificially generated datasets that replicate the statistical properties, inter-variable relationships, and behavioral patterns of real patient populations without containing any identifiable personal data. The datasets are not copies, masks, or tokenized versions of real records. They are generated from models that have learned the underlying structure of a population and can produce new, statistically faithful records on demand.

This distinction matters enormously from a regulatory and legal standpoint. Because the data never originated from a real individual, it is not subject to the same transfer restrictions, consent frameworks, or re-identification risk calculations that govern real patient data. A synthetic clinical cohort can be shared with a contract research organization in another country in minutes rather than months.

For pharma and biotech research teams specifically, this unlocks several capabilities that were previously constrained by data access timelines:

Pipeline and infrastructure testing can begin before the first real patient record arrives, allowing teams to validate CDISC transformations, data model assumptions, and analytics pipelines on production-shaped data from day one.

AI and machine learning model development can proceed on synthetic patient populations that match the statistical signatures of the intended real-world cohort, without waiting for trial data to accumulate.

External collaboration with CROs, academic partners, and third-party vendors can happen immediately, without legal review for every data share.

Rare disease research can scale beyond what real-world patient volumes allow, by generating statistically realistic augmented cohorts that expand the effective size of small populations.

Synthetic Data in Drug Discovery: From Molecules to Clinical Pipelines
The application of synthetic data in pharma begins earlier in the pipeline than most teams realize. In early-stage drug discovery, one of the core AI challenges is data sparsity across pharmacokinetic and drug-target interaction datasets. These datasets are often collected independently across different studies with limited overlap, making it difficult to build predictive models that span multiple compound properties simultaneously.

Generative models trained on existing molecular datasets can produce synthetic pharmacokinetic data that closely resembles real univariate and bivariate distributions, allowing researchers to fill in the gaps across datasets that would otherwise remain disconnected. In 2025, NVIDIA released a synthetic dataset called SAIR containing over five million 3D protein-ligand structures. Despite being entirely artificial, models trained on SAIR demonstrated the ability to predict binding affinities exponentially faster than traditional methods. For a research team screening thousands of candidates in early discovery, this kind of synthetic augmentation can shift the candidate selection timeline from years to months.

At the clinical candidate and trial design stages, synthetic data enables teams to run simulation studies on virtual patient cohorts before any real recruitment begins. Eligibility criteria can be stress-tested against a synthetic population to identify edge cases in the protocol design. Recruitment assumptions can be validated. Statistical power calculations can be refined using more realistic distributional assumptions rather than historical rules of thumb.

The Synthetic Control Arm: Rewriting Clinical Trial Economics

One of the most significant near-term applications of synthetic data in pharma is the synthetic control arm. In randomized controlled trials, the control arm exists to provide a comparator population that receives standard of care or placebo rather than the experimental treatment. For many indications, especially oncology and rare diseases, this structure creates ethical and operational challenges that slow trials and increase costs substantially.

Recruitment accounts for approximately 30% of total trial costs, with each patient costing roughly 6,500 dollars to enroll and 19,000 dollars to replace if they drop out. Dropout rates of 25 to 30% are common, and some trials have reported losses of up to 70% of enrolled patients. In precision oncology trials, where therapies target specific molecular subgroups, finding enough qualifying patients to populate a meaningful control arm can take years.

Synthetic control arms allow researchers to generate virtual patient cohorts that match the statistical and clinical characteristics of the target population, providing a robust external comparator without requiring real patients to be placed on placebo when an experimental therapy is available. A study presented at the ESMO Congress 2025, involving over 19,000 patients with metastatic breast cancer, demonstrated that AI-generated synthetic datasets using conditional generative adversarial networks achieved strong agreement with real data survival outcome analyses while quantifying and mitigating re-identification risks.

Privacy, Compliance, and the Regulatory Landscape

A frequent hesitation among pharma research leaders is whether regulators will accept research supported by synthetic data. The landscape is moving more decisively than many teams expect.

In January 2025, the FDA issued guidance titled Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products, establishing a risk-based credibility assessment framework for AI-generated data used in regulatory submissions. In January 2026, the EMA and FDA jointly proposed ten principles for good AI practice in evidence generation and medicine monitoring, directly supporting the integration of AI-generated data into the regulatory pathway.

Regulators are clear on one point: synthetic data does not replace real clinical evidence for primary safety and efficacy claims. But they increasingly recognize its value for everything surrounding those boundaries, including infrastructure testing, AI model training, statistical simulation, protocol optimization, and external data sharing. The direction of travel is toward responsible integration, not restriction.

For organizations operating under HIPAA, GDPR, or similar frameworks, the architecture of synthetic data generation matters significantly. Platforms that generate synthetic data from statistical models rather than from masked or tokenized production records carry a fundamentally different compliance posture. Because no real personal data enters the generation pipeline, there is no re-identification risk to calculate and no data transfer agreement to establish before sharing the output.

Where SyntheholDB Fits into Pharma and Biotech Workflows?

SyntheholDB was built to solve the specific problem that flat-file synthetic data tools do not address: the need for fully relational, multi-table synthetic databases that preserve schema structure, foreign key constraints, cross-table correlations, and domain-specific behavioral rules.

For pharma and biotech engineering and data teams, this distinction is critical. The data that drives clinical operations does not live in single tables. Electronic health records span patients, providers, encounters, diagnoses, prescriptions, and lab results, all connected through relational keys. A synthetic cohort that preserves only marginal distributions of individual columns but breaks the relationships between those columns is not useful for testing a clinical data pipeline, validating a CDISC transformation, or training a model that depends on longitudinal patient structure.

SyntheholDB ships with a pre-built Healthcare EHR schema that includes patients, providers, encounters, diagnoses, and prescriptions at production-relevant scale. Teams can describe their specific data model in plain English and receive a fully populated synthetic database in under sixty seconds, with referential integrity validated across all tables before export. The platform includes domain-aware correlations that enforce clinical logic at the record level: a fatal adverse event is never generated with a severity classification of mild, and a resolved patient encounter always carries a valid close date.

For compliance-sensitive pharma environments, SyntheholDB is certified under SOC 2 Type II, ISO 27001, HIPAA, and GDPR. Enterprise deployments run fully air-gapped on-premise with no external LLM calls in the generation or validation path, satisfying the data residency requirements of Tier-1 healthcare organizations and the strictest regulatory environments globally.

Five Specific Use Cases Pharma and Biotech Teams Can Activate Today

Clinical Data Infrastructure Testing Before Trial Data Arrives

Research data systems including EDC platforms, CTMS integrations, and biostatistics pipelines can be fully validated against production-shaped synthetic data before a single real patient record enters the system. This eliminates the months of delay that currently occur between protocol finalization and the first meaningful infrastructure test.

AI Model Development Without PHI Exposure

Predictive models for patient stratification, dropout prediction, adverse event classification, and endpoint analysis can be trained and iterated on synthetic EHR datasets that match the statistical profile of the target population. No data use agreement is required, no IRB approval, and no waiting period before the team can begin building.

CRO and Vendor Onboarding Without Legal Review

Every time a sponsor shares data with a CRO, academic partner, or technology vendor, a legal and compliance process is triggered. With synthetic databases, teams can hand off fully relational, production-shaped datasets to external partners immediately, without exposing any patient information or initiating a data transfer review.

Rare Disease Cohort Augmentation

For programs targeting conditions affecting fewer than 100 individuals globally, synthetic data can expand the effective size of available populations for statistical modeling, biomarker analysis, and trial simulation, making it possible to generate meaningful evidence where real-world data volumes are simply too small to support it.

Regulatory Submission Preparation and Audit Readiness

Every SyntheholDB export includes per-run fidelity, privacy, and utility scores, creating an auditable record of the synthetic generation process that regulators and internal compliance teams can review. This supports the transparency and governance requirements emerging from both FDA and EMA AI guidance frameworks.

The Shift From Experimental to Strategic

Clinical cancer research teams published a review in Nature Reviews Cancer in February 2026 describing synthetic data as having the potential to transform data sharing, scientific collaboration, and clinical trial design at scale. The emphasis was on rigorous validation and responsible oversight as the path to realizing that potential, not as barriers to it.

The organizations that will close the gap between data availability and research velocity are the ones that stop treating synthetic data as a workaround and start treating it as a designed-in component of their data architecture. The research is there. The regulatory framework is forming. The tooling has matured to the point where generating a fully relational, clinically coherent, compliance-ready synthetic database takes under sixty seconds.

The bottleneck was never the science. It was always the data.

Ready to eliminate data access delays from your research pipeline? Explore SyntheholDB at db.synthehol.ai and generate your first healthcare database in under 60 seconds. No credit card required.

SyntheholDB for Pharma & Clinical Research Teams: Stop Letting Data Access Kill Your Pipeline

Jitendra Devabhaktuni — Tue, 23 Jun 2026 12:57:34 +0000

Published on dev.to · Target audience: Pharma engineers, CROs, clinical data architects, bioinformatics leads

You are three weeks from a Phase II database lock. Your data engineer needs a realistic copy of the trial database to stress-test the migration script. Your compliance officer says no. Your DBA can't spin up a sanitized copy in time. Your lead developer is working against an empty schema.

This isn't a hypothetical — it's the default state of clinical data engineering in 2026.

The bottleneck is not compute, not modeling talent, not even regulatory appetite. It is the structural impossibility of sharing production clinical trial data with the people who need it most: the engineers, QA teams, and ML leads who build the systems that data flows through.

SyntheholDB was architected to break that bottleneck — not with anonymization workarounds, but by generating production-shaped relational databases from scratch, with no real patient information to protect in the first place.

Why Faker and One-Off Scripts Are Killing Your Clinical Dev Environments

Every pharma data team has a version of this: a Python script in a forgotten repo, seeded with numpy.random calls, producing flat CSVs that roughly resemble a CDASH domain. It worked once. Now, three protocol amendments later, it generates data that violates your inclusion criteria, ignores your visit window logic, and produces patient timelines that no IRB would ever see in real life.

The core problem isn't the script. It's the abstraction mismatch: tools like Faker generate independent rows. Clinical databases are relational systems — patients link to visits, visits link to adverse events, adverse events link to concomitant medications, all governed by complex cross-table business rules.

When your test environment doesn't enforce those relationships, your QA is signing off on logic that will break in production. Every join fan-out that diverges from real behavior, every foreign key constraint that silently disappears in staging — these are deferred production bugs.

SyntheholDB takes a schema-first, constraint-aware approach. You import your actual schema (Postgres, MySQL, or a schema file), define your referential rules once — "no adverse event without a linked subject," "no dispensation record without an active arm assignment" — and the platform preserves those relationships across every generated row.

What SyntheholDB Actually Generates (And Why It Matters for CROs)

SyntheholDB is not a dataset generator. It is a relational synthetic database engine — the distinction matters enormously for contract research organizations running multi-site trials.

Here's the architectural pipeline, directly relevant to clinical data:

1. AI Schema Builder — Describe your data model in plain English, or import CSVs from your real EDC export. The system infers column types, relationships, and foreign-key hierarchies automatically. For a pharma team, this means you can describe "a Phase II oncology trial with subjects, visits, RECIST measurements, SAEs, and prior medications" and get a coherent multi-table schema without writing a single DDL line

2. Correlation Studio — This is where clinical realism lives. You can tune cross-column correlations: force age to scale with comorbidity count, make baseline ECOG scores correlate with early discontinuation rates, align lab values to treatment arm assignments. This is the difference between data that looks like a trial and data that behaves like a trial.

3. Constraint Planner Agents — A specialized agent layer handles referential integrity, composite keys, and many-to-many relationships before generation fires. Every row that hits your export has passed constraint validation. No orphaned records, no broken audit trails.

4. PII Labeler — After generation, a pattern scan labels any sensitive-shaped fields (numeric identifiers that resemble SSNs, phone-shaped strings, date patterns that could indicate DOB). This matters for regulated submissions: you want documentation that the data was assessed for re-identification risk, even when it's synthetic.

5. Export in CSV, SQL, or Parquet — The generated database lands in your pipeline in whatever format your downstream systems expect.

The Compliance Architecture: HIPAA, GDPR, and the Synthetic Data Exception

Here's what most clinical data engineers don't fully operationalize: HIPAA explicitly permits the creation of synthetic data from PHI, provided the synthesis itself follows appropriate safeguards. The HIPAA Privacy Rule's de-identification pathway allows covered entities to use PHI to create information that is not individually identifiable — and mathematically synthesized data satisfies that requirement.

The more important point for pharma: SyntheholDB generates data from statistical models, not from production records. There is no masking layer, no pseudonymization, no "real data minus names." The generation engine never ingests your production trial data — it learns schema shape and rule constraints, then samples from statistical distributions. This means the output is not subject to HIPAA's downstream restrictions. You can hand it to a CRO partner, an offshore QA vendor, or an AI team without triggering a Business Associate Agreement review cycle.

For EU-based sponsors operating under GDPR, the same logic holds: synthetic data that contains no actual patient records does not constitute personal data under Article 4(1), removing the cross-border data transfer restrictions that have historically strangled multinational trial data sharing.

For teams in regulated environments, SyntheholDB's enterprise tier offers fully air-gapped, on-prem deployment — no external LLM calls in the generation or validation path. This is a hard architectural requirement for Tier-1 pharma companies where data cannot leave the firewall under any circumstances.

The platform ships SOC 2 Type II, ISO 27001, HIPAA, and GDPR certifications.

Three High-Impact Use Cases for Clinical Research Teams

1. Pre-Lock Migration Testing

Before a database lock, your data management team needs to validate migration scripts, transformation logic, and CDISC conversion pipelines against a dataset that behaves like the trial. Using a production copy is a compliance risk. Using toy data means your testing is fiction.

SyntheholDB lets you generate a synthetic replica of your trial database — correct schema, correct relationships, realistic distributions — and run your full ETL battery against it. When something breaks, it breaks against synthetic data, not PHI.

2. AI/ML Model Development Without a Data Governance Queue

Regulatory AI in pharma — signal detection in pharmacovigilance, cohort enrichment models, dropout prediction — requires large, realistic training datasets. Waiting on data governance approval for each ML experiment is the primary reason pharma AI teams iterate at 10% of the speed of their counterparts in fintech.

With SyntheholDB, your ML engineer can generate 50,000 synthetic subject records with realistic lab trajectories, SAE profiles, and visit completion patterns in minutes — no approval required, no PII risk, no audit trail anxiety. Research confirms that models trained on high-fidelity synthetic health data achieve performance comparable to those trained on real data for risk assessment and cohort development tasks.

3. Vendor and Partner Data Handoffs

When a third-party statistical analysis vendor, an academic collaborator, or a regulatory affairs consultant needs a copy of the trial structure to scope their work, the legal review cycle typically takes weeks. The data they need is schema-level and relational — not actual patient records.

SyntheholDB generates a structurally faithful, fully populated synthetic version of that database. The vendor gets what they need to start their scoping work. Your legal team never enters the loop.

How SyntheholDB Fits Within the Synthehol Platform

SyntheholDB is part of the broader Synthehol synthetic data platform, which is designed to support different data needs across research, development, analytics, and compliance workflows.

At its core, SyntheholDB enables organizations to generate realistic synthetic databases while preserving the structure, relationships, and integrity of the original data. This makes it ideal for testing, development, validation, and secure data-sharing scenarios where access to real data is restricted.

The Synthehol platform also includes solutions for generating synthetic datasets in multiple formats for analytics and AI initiatives, as well as privacy-focused capabilities that help organizations protect sensitive information while maintaining data utility.

Together, these solutions help organizations accelerate innovation, improve collaboration, reduce data-access bottlenecks, and support privacy and regulatory requirements without relying on sensitive production data.

The distinction between DB and Dataset is clinically significant. Most synthetic data vendors operate at the flat-file level — they generate rows. Clinical trial data is a system of interdependent tables. SyntheholDB operates at the database level, which is the correct abstraction for EDC exports, SDTM/ADaM datasets with parent-child relationships, and safety databases with multi-table event structures.

The Regulatory Horizon: Why This Matters Now

The EU AI Act enters enforcement in Q3 2026, and SR 11-7 model risk guidance now explicitly applies to generative AI outputs. Every synthetic dataset used in a regulatory submission context will need per-run fidelity, privacy, and utility scores — the audit artifact that second-line risk functions require before approving AI-generated inputs.

SyntheholDB ships those scores on every generation run. This is not a feature — it is a compliance precondition for any pharma company planning to use synthetic data in a regulatory context in the next 24 months.

The FDA is beginning to explore synthetic data as part of its Real-World Evidence framework, though definitive guidance on synthetic data in submissions remains pending. The EMA has not yet issued concrete statements. This regulatory ambiguity makes auditability — not just data quality — the deciding factor in platform selection for pharma teams. You need a system that produces a traceable, defensible record of how synthetic data was generated, validated, and scored.

Getting Started: A Clinical Data Engineer's 60-Minute Experiment

The fastest way to evaluate SyntheholDB for your team is a concrete, single-sprint experiment:

Export your SDTM shell or pick a CDISC-adjacent schema (DM, AE, CM, EX, VS — five related domains).
Import that schema into a SyntheholDB workspace at db.synthehol.ai.
Define two or three clinical rules: "No AE without a subject in DM," "EXDOSE correlates with AESTDTC proximity."
Generate 10,000 subjects across all linked domains.
Run your existing data validation scripts (Pinnacle 21, custom SAS/R checks) against the output.

Measure: How many validation failures are caught against synthetic data that would have been caught in UAT? How long did environment setup take compared to your current process?

If the answer suggests your current test environments are politely lying to you — which they almost certainly are — you have a concrete internal case for adopting synthetic data as infrastructure, not as a one-off script.

The free tier at db.synthehol.ai requires no credit card and generates up to 1,000 rows per run, enough to validate the concept on a realistic CDISC schema.

SyntheholDB launched on Product Hunt in May 2026 and is available at db.synthehol.ai. The full Synthehol platform suite is at synthehol.ai.

Creating HIPAA-Safe Synthetic Patient Data for Healthcare App Testing

Jitendra Devabhaktuni — Tue, 16 Jun 2026 11:30:41 +0000

A Technical Guide for Health-Tech Developers, EHR Vendors, and Compliance Teams

Healthcare software teams need realistic patient data to test applications, validate workflows, train machine learning models, and demonstrate products. However, using real patient information—even in non-production environments—creates significant privacy, security, and compliance risks.

Synthetic patient data offers a practical alternative. When generated correctly, synthetic datasets preserve the statistical characteristics and clinical realism of real populations without exposing protected health information (PHI).

This guide explains how to create, validate, and govern HIPAA-safe synthetic patient data for healthcare application testing.

What Is Synthetic Patient Data?

Synthetic patient data is artificially generated information that mimics the structure, relationships, and characteristics of real healthcare records without directly representing actual individuals.

Examples include:

Patient demographics
Diagnoses and procedures
Medication histories
Laboratory results
Encounter records
Insurance information
Clinical notes
Vital signs and longitudinal health data

Unlike anonymized or de-identified records, fully synthetic data is generated rather than transformed from existing patient records.

Why Healthcare Organizations Need Synthetic Data

1. Regulatory Compliance

Using production patient data in development or QA environments may expose organizations to HIPAA violations, data breaches, and audit findings.

Synthetic data reduces:

Unauthorized PHI exposure
Insider risks
Third-party vendor access concerns
Compliance overhead

2. Faster Development Cycles

Developers can access realistic test datasets immediately without lengthy approval processes.

Benefits include:

Rapid environment provisioning
Continuous integration testing
Automated quality assurance
Safer bug reproduction

3. Improved Security

Synthetic datasets eliminate many risks associated with:

Lost backup files
Shared test environments
External contractors
Cloud-based development systems

4. Better Edge-Case Coverage

Synthetic generators can intentionally create:

Rare diseases
Complex comorbidities
Unusual medication interactions
Extreme laboratory values

These scenarios are often difficult to obtain from real-world datasets.

Understanding HIPAA Requirements

HIPAA protects identifiable health information, including:

Names
Addresses
Dates of birth
Phone numbers
Medical record numbers
Social Security numbers
Biometric identifiers
Photographs
Any information that can reasonably identify an individual

For testing purposes, organizations should ensure synthetic datasets contain no direct or indirect linkage to real patients.

The goal is not merely de-identification but the complete elimination of re-identification risk.

Synthetic Data vs. De-Identified Data

Characteristic	Synthetic Data	De-Identified Data
Based on real patients	Not necessarily	Yes
Contains original records	No	Yes
Re-identification risk	Very low when properly generated	Variable
HIPAA concerns	Significantly reduced	Still requires governance
Testing flexibility	High	Moderate

De-identification removes identifiers from real records. Synthetic generation creates entirely new records.

Approaches to Synthetic Data Generation

Rule-Based Generation

The simplest method uses predefined rules and probability distributions.

Example:

Age: 18–90
Hypertension prevalence: 32%
Diabetes prevalence: 11%

Advantages:

Easy to implement
Transparent
Predictable

Limitations:

Limited realism
Weak correlation modeling

Statistical Modeling

Statistical approaches preserve relationships among variables.

Examples:

Bayesian networks
Markov models
Copula-based generators

Benefits:

Better population realism
Maintains variable dependencies

Challenges:

More complex implementation
Requires statistical expertise

Machine Learning–Based Generation

Advanced systems use AI models trained on real healthcare datasets.

Common approaches:

GANs (Generative Adversarial Networks)
Variational Autoencoders (VAEs)
Diffusion models
Large Language Models for clinical text

Benefits:

Highly realistic records
Captures complex relationships

Risks:

Potential memorization of training data
Requires privacy safeguards

Designing a HIPAA-Safe Synthetic Data Pipeline

Step 1: Define Testing Requirements

Identify what the application needs to test.

Examples:

Patient registration workflows
Clinical decision support
Billing processes
EHR interoperability
FHIR API integrations

Avoid generating unnecessary data elements.

Step 2: Build a Clinical Data Model

Include realistic healthcare entities:

Patient

{
  "patient_id": "SYN000123",
  "gender": "Female",
  "age": 54
}

Encounter

{
  "encounter_type": "Outpatient",
  "date": "2026-01-15"
}

Diagnosis

{
  "icd10": "E11.9",
  "description": "Type 2 diabetes mellitus"
}

Medication

{
  "rxnorm": "860975",
  "drug": "Metformin"
}

Step 3: Generate Clinically Consistent Records

Relationships must make medical sense.

Example:

A patient with:

Type 2 diabetes
Elevated HbA1c
Metformin prescription

is clinically plausible.

A patient with:

Pediatric age
Geriatric medication profile
Pregnancy diagnosis

may indicate unrealistic generation.

Step 4: Validate Against Privacy Risks

Perform privacy testing such as:

Nearest-Neighbor Analysis

Determine whether synthetic records closely resemble source patients.

Membership Inference Testing

Assess whether attackers can infer that a real patient existed in training data.

Record Linkage Testing

Evaluate whether external datasets could identify individuals.

Best Practices for Synthetic Clinical Notes

Free-text notes are among the highest-risk data types.

Avoid:

Direct note redaction only
Copying clinician narratives
Template cloning

Recommended approaches:

Generate notes from structured data
Use privacy-preserving language models
Apply entity detection and filtering
Conduct PHI leakage scans

Example:

Instead of:

Patient Jane Smith arrived from 123 Main Street.

Generate:

The patient presented with worsening shortness of breath over the past three days.

Supporting Healthcare Standards

Synthetic datasets should support industry standards including:

HL7
FHIR
ICD-10
SNOMED CT
LOINC
RxNorm

This enables realistic interoperability and integration testing.

Quality Assurance Checklist

Before releasing a synthetic dataset:

Privacy Validation

No direct identifiers
No copied patient records
No training-data memorization
Re-identification risk assessed

Clinical Validation

Diagnoses are plausible
Lab values align with conditions
Medications match diagnoses
Longitudinal histories are coherent

Technical Validation

Schema compliance verified
APIs tested successfully
Data formats validated
Edge cases represented

Compliance Validation

Governance documented
Data lineage recorded
Generation methodology reviewed
Security controls applied

Common Mistakes to Avoid

Mistake 1: Assuming De-Identified Data Is Synthetic

Removing names does not create synthetic data.

Mistake 2: Ignoring Clinical Relationships

Randomized datasets often produce impossible medical scenarios.

Mistake 3: Skipping Privacy Evaluation

Even synthetic data should undergo privacy risk assessment.

Mistake 4: Neglecting Rare Populations

Testing should include:

Pediatric patients
Geriatric patients
Chronic disease populations
High-utilization patients

Mistake 5: Copying Clinical Notes

Narrative text frequently leaks PHI even after redaction.

Governance Recommendations

Organizations should establish:

Data Generation Policies

Define:

Approved generation methods
Validation procedures
Acceptable risk thresholds

Audit Documentation

Maintain records of:

Source datasets
Generation algorithms
Privacy assessments
Validation reports

Access Controls

Even synthetic datasets should be governed through:

Role-based access
Change management
Audit logging
Secure storage

Conclusion

Synthetic patient data has become a critical tool for modern healthcare software development. When properly generated and validated, it enables realistic testing, accelerates innovation, and significantly reduces privacy risks associated with using production health records.

The most effective HIPAA-safe synthetic data programs combine:

Strong privacy engineering
Clinical realism
Regulatory governance
Continuous validation

By treating synthetic data generation as both a technical and compliance discipline, healthcare organizations can build safer applications while maintaining patient trust and regulatory confidence.

From Clean CSVs to Production‑Shaped Data: A Practical Guide for Academic ML and Data Engineering

Jitendra Devabhaktuni — Mon, 08 Jun 2026 11:07:38 +0000

Your Research Deserves Better Than Toy CSVs

If you work in a university lab, your data setup might look familiar: a shared drive full of CSVs, a few “legendary” notebooks that only one person truly understands, and a pipeline that behaves perfectly on a small curated dataset but quietly breaks as soon as the data gets messy.

At the same time, expectations around research are much higher now. It is no longer enough to say “this model works on Dataset X.” Reviewers, funders, and industry collaborators want to know whether your idea survives noisy conditions, fits into an end to end system, and has any chance of working in a real product.

That gap between neat benchmarks and messy reality is exactly where production‑shaped synthetic data becomes interesting.

The Limits of Dataset‑Centric Thinking
Most academic workflows are still built around individual datasets. The pattern is very familiar:

Find a dataset that roughly matches the problem.

Clean it, preprocess it, maybe create a few engineered features.

Train and evaluate a model, then report metrics.

This is a solid approach for early exploration and teaching basic ML. The problem appears when your research question is really about systems rather than single models.

In real settings, you are rarely working with a single table. Instead, you are dealing with databases that:

Contain multiple related tables with primary and foreign keys

Evolve their schemas as the product or study evolves

Accumulate logs, events, and derived views over time

On top of that, the data itself is messy. It has missing values, inconsistent states, odd edge cases, and rare but crucial events. A static, clean CSV simply does not capture these dynamics, no matter how clever the model is.

What “Production‑Shaped” Actually Means?

When people talk about “production‑like data,” it can sound vague. It helps to make it concrete.

A production‑shaped test database is one that mirrors the structure and behavior of a real application without using real user records. That typically means:

Multiple tables with realistic relationships

Constraints and foreign keys that the data must obey

Patterns over time such as seasonality, bursts of activity, or gradual drift

A healthy amount of “mess”: missing values, skewed distributions, rare events

The goal is not to clone an existing production database. The goal is to create a safe environment that behaves enough like production to expose interesting failure modes and system‑level questions.

Once you have that, the types of research you can do expand dramatically.

Why Academic Labs Benefit From Production‑Shaped Synthetic Data?

For many labs, the hardest part of system‑level research is not the algorithm. It is access to realistic data. Industry partners cannot simply hand over production databases, and public datasets rarely reflect real schemas or workflows.

This is where synthetic data, used thoughtfully, becomes a powerful research tool.

First, it protects privacy and compliance. You experiment on artificial data that never belonged to real users, while still respecting realistic structures and distributions.

Second, it unlocks more realistic failure modes. When the data includes edge cases, inconsistent states, and shifting behavior, your monitoring, validation, and evaluation ideas get tested in conditions that feel closer to real deployments.

Third, it bridges the gap between academia and industry. Students and researchers gain experience with the kind of complexity they will see outside the lab, without needing direct access to production environments.

What To Look For in a Synthetic Data Setup?

If you want synthetic data to help with system research, not just model benchmarking, some capabilities matter more than others.

You will typically want:

Relational structure
The ability to define and generate multiple tables, with primary keys, foreign keys, and realistic cardinality patterns (one‑to‑many, many‑to‑many, etc.). This is essential if you care about joins, integrity constraints, and cross‑table logic.

Controlled “messiness”
A way to introduce missing values, partial records, inconsistent states (like orphaned rows), and outliers on purpose. If everything is too clean, you are back to the original problem.

Behavior over time
Data that changes in ways that mimic real activity. For example, daily or weekly cycles, traffic spikes, gradual shifts in user behavior, or rare but important events. This matters for research on drift, retraining strategies, and monitoring.

Reproducibility
The ability to generate the same environment from a configuration or prompt, so other labs can recreate it. This helps move reproducibility beyond “here is my CSV” to “here is how you recreate the world my system was tested in.”

When these pieces come together, a synthetic environment becomes much more than a random data dump. It becomes a reusable testbed for ideas.

How To Introduce Production‑Shaped Data Into Your Lab?

The good news is that you do not need a massive transformation to get started. You can introduce production‑shaped data in a very targeted way.

Upgrade Your Teaching Examples Instead of a single flat dataset, design a small synthetic application for your course:

An online store with users, orders, products, and reviews

A clinic or hospital setting with patients, visits, diagnostics, and billing

A SaaS platform with tenants, accounts, events, and logs

Then, use this environment to teach:

SQL across multiple tables

ETL and data pipeline design

Testing, monitoring, and incident handling for data workflows

Students will encounter challenges that are closer to what they will see on real teams, without needing access to sensitive data.

Prototype System‑Level Ideas Safely If you are exploring topics like evaluation, data quality, observability, or MLOps:

Sketch the real-world system you have in mind.

Map its entities, relationships, and typical edge cases.

Build or generate a synthetic database that matches this design.

Run your entire idea end to end on that environment, not just the model.

You will often uncover questions and failure modes that do not appear when you work only with a benchmark table.

Support Collaborations Without Moving Data When collaborating with industry partners, the biggest sticking point is often data sharing. A useful pattern is:

Partners share schemas, constraints, and high‑level statistics instead of raw records.

You recreate a synthetic version of that world in your environment.

Experiments, pipeline designs, and algorithms are developed against the synthetic stand‑in.

This preserves privacy while still letting both sides talk about realistic problems and solutions.

A Simple Exercise To Try This Week

To make this concrete, take one of your current projects and ask yourself:

What real application is this dataset trying to represent?

If that application were live today, what would the underlying database look like?

Which tables and relationships would exist?

What messy situations would show up over time?

Once you have that picture, imagine you could spin up that kind of database on demand, populated with synthetic data, and refresh or tweak it for different experiments.

How would that change the questions you ask, the way you design your experiments, and the way you teach others about your work?

The Phantom Schema Problem: Why Your Database Contract Breaks Before Your Tests Do

Jitendra Devabhaktuni — Thu, 04 Jun 2026 11:29:16 +0000

There's a class of production failures that are almost impossible to catch with standard testing practices because they don't violate any test. The code runs. The queries execute. The application behaves correctly against every dataset it's ever seen. And then a new environment, a new integration, or a slightly different data state exposes a contract assumption that was never written down anywhere — and the whole thing breaks in a way that takes hours to diagnose.

Call it the phantom schema problem. It's the gap between the schema your database enforces and the schema your application actually depends on.

The Difference Between Enforced and Assumed Constraints

Modern relational databases enforce a surprisingly small subset of the constraints that real applications depend on. Foreign keys, NOT NULL declarations, unique indexes, data types — these are the things the database will actually reject at write time. They're the explicit contract.

But applications build up a far larger set of implicit assumptions over time. Assumptions that a particular column will never exceed a certain length in practice even though the type allows more. Assumptions that two tables will always have a matching row even though there's no foreign key enforcing it. Assumptions that a status field will contain one of four known values even though it's a VARCHAR with no CHECK constraint. Assumptions that date ranges across linked records will always be logically consistent even though nothing enforces that consistency at the database level.

These assumptions live in the application code, not the schema definition. They were reasonable when they were made because the data at the time supported them. They become phantoms when the data evolves in ways the code never anticipated.

Why This Is Harder to Test Than It Sounds?

The standard response to this class of problem is "write more tests." But tests can only validate assumptions you've already made explicit. A phantom schema assumption by definition is one nobody wrote down — which means nobody wrote a test for it either.

More specifically, the problem with catching phantom schema violations in test environments is that test data is almost always too well-behaved to trigger them. Handwritten fixtures reflect the scenarios the author thought of. Generated data without controlled distributions reflects the average case. Neither reliably produces the specific combination of values that exposes an implicit constraint violation — because that combination is, by nature, one that felt safe to assume away.

The violation surfaces when real users in production create data states that developers never modelled during development. A user who updates their profile in a sequence the UI wasn't designed for. A batch job that creates records in a slightly different order than the application assumes. A third-party integration that sends a valid but unexpected value in a field your code treats as an enum without declaring it as one.

The Contract That Lives in Your JOIN Logic

The most dangerous phantom schema assumptions are the ones embedded in JOIN logic.

When you write a JOIN, you're making an implicit claim about the relationship between two tables — not just that the foreign key exists, but that the cardinality, the nullability, and the data distribution on both sides of the join will behave in a way that makes the query result meaningful.

A LEFT JOIN that was written assuming the right-side table would "almost always" have a matching row behaves very differently when 30% of production records have no match. An INNER JOIN that worked perfectly during development silently drops records in production when the join condition isn't met for edge case users. Aggregations built on top of those joins produce subtly wrong numbers that pass every validation check because nobody defined what "correct" looks like for the edge case population.

These aren't bugs in the traditional sense. The query is syntactically valid. The result is technically accurate given the data. The problem is that the data state the query was designed for and the data state production creates are different things — and the gap between them was never modelled in testing.

Phantom Schema and Synthetic Data

This is where synthetic data generation with controlled distributions changes the problem meaningfully.

When you generate test data by specifying populations rather than examples, you can deliberately model the data states that expose phantom schema assumptions. You can generate a dataset where 25% of users have no matching row in the table your JOIN assumes will always have one. You can produce records where the implicit enum values your code depends on include an unexpected but technically valid variant. You can create cardinality distributions that stress the aggregation logic that only breaks when the ratio of parent to child records falls outside the range you assumed during development.

The phantom assumption doesn't become visible until data exists that violates it. Synthetic generation with controlled edge case distributions is the fastest way to create that data before production users do.

The specific capability that matters here is relational consistency at scale — generating linked tables where the relationships between records reflect distributions you specify rather than distributions that happen to be convenient. A generator that produces flat tabular data won't surface JOIN-layer phantom assumptions. One that maintains referential integrity across a full relational schema while respecting the cardinality parameters you define will.

That's the gap SyntheholDB was built to close. Describe your schema and the distributions you want to stress-test — including the edge case populations that expose implicit contract assumptions — and generate a relationally consistent dataset that challenges your application rather than confirming it. Free tier at db.synthehol.ai, no card required.

The Discipline Worth Adopting

The most robust engineering teams treat phantom schema assumptions as a first-class concern rather than an afterthought. They document implicit constraints alongside explicit ones. They generate test data that includes the populations most likely to violate those constraints. And they treat a test suite that only runs against well-behaved data as an incomplete one — regardless of what the coverage metrics say.

The schema your database enforces is the floor. The schema your application actually depends on is the ceiling. The distance between them is where your most interesting production bugs live.

Your QA Team Is Testing the Wrong Thing and Your Data Is Why

Jitendra Devabhaktuni — Sat, 30 May 2026 03:56:21 +0000

There's a conversation that happens in almost every post-mortem I've seen from engineering teams that ship a bug into production.

Someone says "but the tests passed." And they did. Every single one. The QA suite ran clean, the staging environment looked fine, and the bug made it through anyway — not because the tests were wrong, but because the data the tests ran against wasn't honest enough to catch it.

This is the QA problem nobody wants to talk about because it's not a process failure or a tooling failure. It's a data failure. And it's hiding inside the thing most teams consider the least interesting part of their testing infrastructure.

What Test Data Is Actually Supposed to Do
Ask most engineers what test data is for and they'll say something like "to make the tests run." That's technically correct and almost entirely useless as a definition.

Test data is supposed to simulate the full range of real conditions your application will encounter in production. Not the clean, expected, happy-path conditions. All of it. The user who fills in every form field correctly but in an unexpected order. The account with a transaction history that spans a decade and has three different currency types. The customer whose subscription tier was migrated three times and whose billing state is technically valid but unusual enough that your discount logic has never seen it before.

When test data doesn't include those scenarios, your tests become a confidence machine that produces false confidence. They pass reliably. They catch nothing new. And the bugs that matter — the ones that affect real users in real edge cases — sail straight through.

The Handwritten Data Problem at Scale

Most QA teams build their test data the same way they've always built it — by hand, incrementally, adding new fixtures as new features ship. It works well enough in the early days when the application is simple and the team is small.

The problem compounds over time in two directions simultaneously.

The first is coverage. Handwritten fixtures reflect the scenarios the person writing them thought of. Senior engineers write more complete fixtures than junior engineers. Tired engineers at the end of a sprint write less thorough fixtures than rested ones. Nobody deliberately writes incomplete test data — it just happens that human imagination has limits, and edge cases by definition are the scenarios nobody imagined clearly enough to write down.

The second is drift. As the schema evolves, fixtures that were accurate when written become increasingly disconnected from production reality. A column gets added. A relationship changes. A new business rule means that a combination of values that was valid twelve months ago is now impossible in production — but the fixture still has it, and the test still runs against it, and the pass rate stays at 100% because the test is validating behavior against a state of the world that no longer exists.

The Coverage Illusion

Here's the part that makes this genuinely dangerous: high test coverage metrics are fully compatible with terrible test data quality.

You can have 95% code coverage and still have every single test running against data that only represents the top 10% of your actual production scenarios. The coverage number tells you how much of your code was executed during the test run. It tells you nothing about whether the data that executed it was realistic enough to surface the bugs that matter.

A QA team running 2,000 tests against handwritten fixtures that all look like well-behaved users is not better protected than a team running 500 tests against generated data that includes churned accounts, failed payments, incomplete profiles, and edge case combinations that actually appear in production. The second team catches more of what matters. The first team has a more impressive dashboard.

What Generated Test Data Changes?

When you move from handwritten fixtures to generated test data with controlled distributions, the first thing that changes is coverage breadth — not in the code coverage sense, but in the scenario coverage sense.

You stop writing test data by imagining scenarios and start specifying populations. Instead of "create a user with these properties," you describe "generate 10,000 users where 15% have incomplete profiles, 8% are in a failed payment state, 5% have accounts over five years old, and 3% have churned and reactivated at least once." The generator handles the variation. Your tests run against a population that reflects production, not a set of examples that reflect what someone thought of on a Wednesday afternoon.

The second thing that changes is consistency. Generated data doesn't drift because you're not maintaining it — you're regenerating it. When the schema changes, you update the generation parameters and regenerate. The fixtures stay current without anyone having to remember to update them.

The third thing — and this is the one QA leads tend to care about most — is that edge case discovery becomes deliberate rather than accidental. You can specify exactly the distribution of unusual states you want to test against, rather than hoping someone thought to write a fixture for them.

How SyntheholDB Fits Into a QA Workflow?

This is the workflow pattern that makes the most practical sense for most QA teams getting started with generated test data.

You describe your schema in plain English — the tables, the relationships, the business logic that should govern value distributions. SyntheholDB generates a relationally consistent dataset where foreign keys resolve correctly across every linked table and the statistical properties you specified are reflected in the output. The PII scan runs automatically before export, so nothing resembling a real customer record ends up in your test environment. The CSV seeds directly into your QA database, your CI pipeline, or your local environment.

The workflow change for the QA team is minimal. The same tests run against the same database. The difference is that the database now contains data that actually challenges the application instead of confirming it. Free tier is live at db.synthehol.ai — no credit card, no configuration overhead.

The Reframe That Matters

Good QA isn't about the number of tests you have. It's about the honesty of the conditions those tests run against.

A test suite running against generated data with realistic distributions — including the edge cases, the failure states, and the unusual combinations that production users generate every day — will catch more meaningful bugs with fewer tests than a suite running against carefully handwritten fixtures that all look like ideal users.

The data is the test. Most teams just haven't treated it that way yet.

The Demo Environment Is a Lie. Here's Why That's Hurting Your Sales.

Jitendra Devabhaktuni — Tue, 19 May 2026 08:21:48 +0000

Sales demos are the most important technical artifact most engineering teams never think about seriously.

The marketing team writes the deck. The founder rehearses the pitch. The AE knows the objection handling cold. And then the prospect asks to see the product in action and everyone quietly holds their breath — because the demo environment is running on data someone cobbled together eight months ago and nobody has touched since.

This is more common than anyone admits. And it costs deals in ways that are almost impossible to attribute correctly because the failure is subtle. The demo doesn't crash. It just doesn't convince.

What a Bad Demo Environment Actually Looks Like
The problems are rarely dramatic. It's not that the product breaks or throws an error on screen. It's that the data looks fake in a way that prospects immediately register but rarely articulate.

Usernames like "Test User 1" and "Test User 2." Order values that are all suspiciously round numbers. A SaaS dashboard showing three customers with identical usage patterns. A fintech product where every transaction is exactly $100. A healthcare platform where every patient was admitted on the same date.

Technically the product is working. But the prospect is sitting there doing mental math — if this is what their demo looks like, what does their actual product look like? If they can't be bothered to make the demo feel real, what does that say about how much they care about the details?

It's a trust signal. And it's going the wrong direction.

The Engineering Team's Blind Spot

Most developers don't think about demo environments as a product problem. It lives in a grey area — not quite production, not quite a test environment, owned by nobody in particular, maintained by whoever last got assigned a sales engineering task.

The result is that demo data gets written once, gets slightly updated when a major feature ships, and slowly drifts further and further from what a realistic version of the product looks like in the hands of a real customer.

And the bigger problem is that realistic demo data is genuinely hard to write by hand. You can write a handful of users easily enough. But to make a SaaS analytics dashboard look like it's being used by a real company with usage patterns that follow a realistic distribution, churned users mixed in with healthy ones, some accounts on the wrong plan, a few power users who skew the averages that takes either a lot of time or a lot of production data you probably shouldn't be using in a demo environment.

Why Production Data in Demos Is a Trap?

The shortcut most teams reach for eventually is pulling a sanitised slice of production data into the demo environment. Real distributions, real patterns, real edge cases. The demo suddenly looks convincing.

And then someone on a sales call asks "is any of this real customer data?" and the answer gets complicated fast.

Even sanitised production data carries risk. Partial anonymisation is reversible more often than people assume. A prospect who works in a regulated industry will notice immediately if your demo data looks like it came from real users — and that's a trust signal going the wrong direction too, for completely different reasons.

For healthcare, fintech, or any product touching personally identifiable information, using production records in a demo environment isn't just a compliance risk. It's a sales risk. The moment a prospect thinks their data might end up in someone else's demo, the deal gets harder.

What the Best Demo Environments Have in Common?

The demos that consistently land well share one characteristic: the data tells a story.

Not a manufactured story. A realistic one. Users with different tenure, different usage patterns, different health scores. Accounts that are doing well and accounts that aren't. Edge cases that show the product handling something difficult gracefully. A distribution that looks like what the prospect's own data might look like in six months if they become a customer.

That kind of data can't be handwritten in an afternoon. It has to be generated with controlled distributions, relational consistency across linked tables, and enough statistical variation to feel real without any actual customer records involved.

How SyntheholDB Changed Our Demo Workflow?

At LagrangeData.ai we obviously use our own product for this. But watching how the demo environment improved when we started generating synthetic relational data instead of handwriting seed scripts was a useful reminder of why we built it in the first place.

The workflow is straightforward. Describe your schema and the distributions you care about, what percentage of users should be churned, what the usage pattern spread should look like, what the account age distribution should be. SyntheholDB generates thousands of rows with relational integrity across every linked table, value distributions that reflect the parameters you set, and a PII scan before export so nothing that resembles a real identifier makes it into the output.

The demo environment went from something we were quietly embarrassed about to something we actively wanted prospects to explore. That shift happened because the data finally looked like it came from a real product used by real people — because statistically, it does.

Free tier at db.synthehol.ai, no card, no setup. Describe your first schema and see what comes back.

The Reframe Worth Making

Demo environments aren't a devops problem or a sales engineering problem. They're a product problem. The data in your demo is part of your product experience for every prospect who sees it.

Treating it that way generating it with the same care you'd apply to any other part of the product is one of the lowest effort, highest impact changes most teams can make to their sales motion.

The deal you lose because your demo data looked fake is a real deal. It just never shows up in your attribution model.

Why Your AI Model Is Only As Good As the Data You Test It On

Jitendra Devabhaktuni — Wed, 13 May 2026 01:33:34 +0000

There's a conversation happening in almost every AI team right now that nobody wants to have out loud.

The model is trained. The benchmarks look good. The demo is convincing. And then it hits a real environment and behaves in ways nobody predicted — not because the model is bad, but because the data it was tested against was too clean, too uniform, and too optimistic to reflect anything close to reality.

This is the quiet problem underneath a lot of AI projects that ship with confidence and underperform in production.

Training Data Gets All the Attention. Test Data Doesn't.

The machine learning community has spent years developing rigorous thinking around training data quality — diversity, bias, distribution drift, labeling accuracy. That thinking is real and it matters. But there's a second data problem that gets a fraction of the attention: the quality of the data you use to evaluate, validate, and stress-test your model before it ships.

Most teams test against whatever data is available. Sometimes that's a held-out slice of the training set. Sometimes it's a manually curated sample of production records. Sometimes it's fixture data someone wrote by hand two sprints ago that's been used ever since because nobody got around to replacing it.

None of these options are good. A held-out training slice shares the same distribution as training data, which means it can't surface edge cases the model hasn't seen. Production records create privacy and compliance exposure the moment they leave the production environment. Handwritten fixtures reflect the happy path the developer imagined, not the messy reality users actually generate.

What Realistic Test Data Actually Needs to Do?

For AI and ML systems specifically, test data needs to do something harder than just fill a table with plausible-looking rows.

It needs to reflect the statistical distribution of real-world inputs — including the long tail. The edge cases. The inputs that are technically valid but unusual. A customer who's been on your platform for eight years and has 400 orders. A user whose transaction history has a three-year gap. An account where every field is populated correctly except one that was corrupted during a legacy migration.

These aren't exotic scenarios. They're what production looks like. And if your model has never seen data shaped like this during evaluation, you won't know it struggles with it until a real user triggers it.
Handwritten fixtures will never get you there. A developer writing fake data imagines normal users. Production is full of people who are anything but.

The Distribution Problem at Scale

Here's where it gets technically interesting.
When you're evaluating a model against a small curated dataset, distribution gaps are manageable. You can eyeball the data, notice what's missing, and patch it. But when your evaluation pipeline runs against thousands or tens of thousands of records — as it should, for any model going into production — manually curating realistic distributions becomes impossible.

What you need is generated data where the distributions are specified, not assumed.

Where you can say "15% of users should have incomplete profiles, 8% should have transactions in a failed payment state, and 3% should have account ages over ten years" — and get a dataset back that reflects exactly those parameters, with relational integrity across every linked table.
That's the difference between test data that validates your model and test data that challenges it.

What This Looks Like in Practice?

At LagrangeData.ai we built SyntheholDB specifically to address this problem for teams working with relational data structures. Instead of writing fixture files or pulling production records, you describe your schema and the distributions you care about in plain English. The generator handles relational consistency — foreign keys resolve correctly across linked tables, value distributions reflect the logic you specified, and edge cases are built into the output rather than discovered in production.

For AI and ML teams the workflow fits naturally into the evaluation pipeline. You define what your test population should look like — including the edge cases you're deliberately trying to surface — generate a dataset that reflects those parameters, and run your evaluation against data that actually tests the boundaries of your model rather than confirming what it already handles well.

The PII scan that runs automatically before export matters here too. The moment you're generating evaluation data at scale, the last thing you want is a generated value that accidentally resembles a real customer record making its way into a shared evaluation environment.

Free to try at db.synthehol.ai — no card, no setup call.

The Shift Worth Making

The teams getting the most reliable model performance in production aren't necessarily the ones with the best training data. They're the ones who are most honest about what their evaluation data is actually testing.
If your test data is too clean, your benchmarks are too optimistic. If it's too narrow, your edge case coverage is an illusion. If it's pulled from production, you're carrying compliance risk into every evaluation run.

Generated synthetic data with controlled distributions isn't a workaround. For serious AI evaluation pipelines, it's the right architecture. The models that behave well in production were tested against data that looked like production — messy, edge-case-heavy, and statistically honest.
That's a solvable problem. It just requires treating test data with the same rigor you already apply to training data.